Introduction
The spread of Acinetobacter baumannii (A. baumannii), a major pathogen responsible for hospital infections, is difficult to control and its infections are difficult to treat owing to its ability to adapt to different environments and its intrinsic resistance to many antibiotics.
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Jiang et al meropenem-based therapies. 6 However, systematic analysis of meropenem-based combination therapies is still lacking. To provide a basis and reference for clinical rationales behind combination therapies using meropenem, we systematically searched and analyzed three mainstream databases to evaluate the in vitro synergistic activity of meropenem with other antibiotics against A. baumannii.
Materials and methods search strategy and selection criteria
A broad literature search on the PubMed, Embase, and Web of Science databases was performed throughout March 2018 by two separate reviewers. Journal articles were selected without limitations on publication date, language, or publication type. Keywords and Boolean operators used for the searches were (meropenem) AND (baumannii) AND (synerg* OR combin*). We also used the related articles function to broaden our search. In addition, reference lists of the selected articles were also manually examined to find relevant studies that were not included in our initial searches.
All meropenem-based in vitro combinations tests (application of traditional testing methods including the checkerboard, Etest, and the time-kill method, which included both the static time-kill and the in vitro dynamic pharmacokinetic/ pharmacodynamic model) were included in this study. Those testing meropenem in combination with compounds that are not available on the market worldwide, and the combination therapies with more than two drugs were excluded.
Data collection and statistical analysis
In this meta-analysis, data were independently extracted by two researchers using a premade data extraction form. From each study, the following information was extracted: 1) first author and the publication year; 2) susceptibility to meropenem; 3) types of antibiotics used; 4) total number of isolates tested; 5) in vitro combination testing methods. Antibiotic breakpoints were set based on the Clinical and Laboratory Standards Institute. Meropenem susceptibility and resistance were defined: susceptible, ≤2 mg/L; intermediate, 4 mg/L; resistant, ≥8 mg/L.
The outcome analyzed in the study was the in vitro synergy activity of combination therapy. For time-kill tests, synergy was defined as ≥2 log 10 (at any time points in 24 hours) colony-forming units/mL decrease between the combination therapy and the most efficient agent, when used alone. With the checkerboard and Etest method, interactions were defined by the fractional inhibitory concentration index (FICI), which was calculated using the following formula: FICI = (MIC AB / MIC A ) + (MIC BA /MIC B ), where MIC AB and MIC BA were the minimum inhibitory concentrations (MIC) of drugs A and B in combination therapy, while MIC A and MIC B were the MIC of drugs A and B tested alone. The FICI value was interpreted as follows: ≤0.5, synergy; >0.5-4, indifference; >4, antagonism. 7 Synergy rates with 95% CI and each isolate reported in a paper were calculated separately for each synergy method, where the number of isolates tested was defined as the sample size and the event was defined as synergy. As the event rates in most studies are 0 or 1, which are not normally distributed, we performed a logit transformation for the event rates. Results from each testing method were subgrouped by antibiotic type. Some time-kill studies utilized multiple drug concentrations on the same bacterial strains, and we chose a more common clinically achievable drug concentration. For studies applying multiple test methods, data of different methods were separately collected and analyzed. All statistical analyses were performed with the Stata 14.0 software (Stata Corporation 2015, College Station, TX, USA). We calculated various pooled synergy rates using both random-and fixed-effects models. Heterogeneity was assessed by I 2 . An I 2 statistic of 0% indicated no observed heterogeneity. We used a fixed-effects model when I 2 <50%; otherwise, the random-effects model was used.
Results
studies included
Our search strategy initially yielded 1,161 potentially relevant citations from PubMed, Embase, and Web of Science ( Figure 1 ). Excluding the studies that did not report any in vitro experiments evaluating the synergistic effect of meropenem-based combinations against A. baumannii, 56 published studies fulfilled the inclusion criteria and were included in this review. The characteristics of each included study are described in Table 1 . In the analysis, 1,228 A. baumannii strains were subjected to 14 Etests, 42 checkerboard microdilution tests, and 40 time-kill assays to evaluate the synergistic activity of meropenem combination therapies using 20 types of antibiotics.
Time-kill data synthesis
Meropenem-polymyxin B combination therapies ( Figure 2) were assessed in ten studies using 30 isolates, and yielded a synergy rate of 98.3% (95% CI, 83.7%-100.0%) with no heterogeneity (I 2 ); the fixed-effect model was applied in the meta-analysis, and no isolates showed antagonism. As only one study was conducted on the meropenem-susceptible strains, subgroup analysis was not performed for this combination therapy. 16, 17, 20, 27, 34, 48, 50, 57, 59, 60 Infection and Drug Resistance 2018:11 submit your manuscript | www.dovepress.com
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In vitro meropenem-based combination against A. Baumannii For meropenem-rifampicin combinations (Figure 3 ), pooling data from 20 isolates in four studies showed that the synergy rate was 89.4% (95% CI, 57.2%-100.0%), and no antagonism was observed. 16, 20, 24, 32 Heterogeneity (I 2 ) for these studies was 51.9%; thus, the random-effect model was utilized in the analysis.
For meropenem-colistin combinations (Figure 4 ), tests conducted on 132 isolates in 12 studies yielded a synergy rate of 60.4% (95% CI, 24.7%-91.8%), and no isolate was antagonistic. 7, 14, 15, 21, 23, 44, 47, 53, 54, 56, 61, 62 Heterogeneity (I 2 ) was calculated to be 89.8%, and thus, the random-effect model was applied in the meta-analysis. There are five studies on meropenem-susceptible strains; however, no detailed information on the number of isolates was found in some of these studies, which resulted in the absence of subgroup analysis.
For meropenem-sulbactam combination therapies ( Figure 5 ), tests were performed on 69 isolates in five studies, and yielded a synergy rate of 54.8% (95% CI, 39.7%-69.6%) with no heterogeneity (I 2 ), and the fixed-effect model was chosen. 8, 14, 21, 46, 53 None of the isolates was antagonistic. Two Figure S1 ), six studies were performed on 36 isolates, which yielded a synergy rate of 24.5% (95% CI, 1.0%-58.4%), and no antagonism was found and heterogeneity (I 2 ) for these studies was 46.5%. 12, 16, 20, 47, 53, 56 Two studies on nine strains tested meropenem-amikacin combinations, and the synergistic effect was found in 0/1 and 8/8 strains, respectively. One study evaluated meropenemciprofloxacin combination, and the synergistic activity was found in 18/40 strains.
checkerboard microdilution data synthesis
For meropenem-polymyxin B combinations ( Figure 6 ), tests were carried out on 99 strains in four studies, and showed a pooled synergy rate of 37.0% (95% CI, 0.0%-100.0%) and heterogeneity (I 2 ) was 98.1%. 13, 26, 39, 51 Owing to its high submit your manuscript | www.dovepress.com
Dovepress
1086
Jiang et al 
1087
In vitro meropenem-based combination against A. Baumannii heterogeneity, we used the random-effect model for statistical analysis. No isolates were found to be antagonistic.
Thirteen studies with 189 isolates tested meropenemcolistin combination therapies and showed a pooled synergy rate of 58.8% (95% CI, 29.4%-85.6%) and a heterogeneity (I 2 ) of 92.3% ( Figure 7) ; thus, the random-effect model was applied in the meta-analysis. 7, 11, 29, 36, 40, 41, 43, 44, 47, 49, 54, 56, 62 Two isolates were found to be antagonistic. There are six studies that include meropenem-susceptible strains; however, no detailed number of isolates was found in some of these studies, which resulted in the unavailability of subgroup analysis. ) of 79.4% was observed, and as a result, we chose the random-effects model. Three isolates were antagonistic. Considering that there was no detailed number of meropenem-susceptible isolates in three studies, the subgroup analysis was not applied. Six studies were performed on 309 strains in the meropenemcefoprazone/sulbactam combinations ( Figure S2 ), yielding a pooled synergy rate of 7.4% (95% CI, 1.4%-16.6%). Heterogeneity (I 2 ) for these studies was 80.6%. 26, 30, 32, 33, 35, 52 Three studies testing meropenem-rifampicin combination therapies ( Figure S3 ) yielded a synergy rate of 56.3% (95% CI, 8.7%-97.8%). 24, 26, 32 Heterogeneity (I 2 ) for these studies was 90.2%. Meropenem-ciprofloxacin combination therapies were tested in three studies ( Figure S4 ), and yielded a pooled synergy rate of 0.3% (95% CI, 0.0%-3.5%). 30, 32, 52 Heterogeneity (I 2 ) was 33.0%. The combination of meropenem and tigecycline was tested in two studies, and seven of 35 strains showed synergy. Two studies tested the effect of meropenem in combination with amikacin, and synergistic activity was found in 67/128 strains.
etest data synthesis
Four studies that evaluated the effect of meropenem-colistin combinations ( Figure S5 ) on 122 isolates yielded a pooled synergy rate of 39.2% (95% CI, 0.0%-97.7%), and heterogeneity (I 2 ) was found to be 95.9%. 31, 45, 55, 62 Three studies consisting of 102 strains investigated the effect of meropenem-sulbactam combinations ( Figure S6 ), reporting a pooled synergy rate of 35.1% (95% CI, 21.4%-50.1%). 37, 38, 55 Heterogeneity (I 2 ) was 52.3%. One study with 40 strains tested the meropenem-rifampicin and meropenem-moxifloxacin combinations, and synergy was found in 1 and 0 strain, respectively. Two studies reported synergistic effect Lenhard et al, 50 2016
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Discussion
The global emergence of MDR A. baumannii has spurred an interest in finding a more effective treatment strategy. The World Health Organization has identified antimicrobial resistance as one of the three most important problems affecting human health and carbapenem-resistant A. baumannii as a critical priority pathogen to help in prioritizing the research and development of new and effective antibiotic treatments. 63 Combining antimicrobials is an effective treatment approach for MDR A. baumannii infections. Reports of meropenembased combination against A. baumannii have been rising steadily during the past few years. Our results indicated that several antibiotics combined with meropenem could act synergistically in vitro against A. baumannii, especially for polymyxin B and rifampicin. Notably, colistin, also known as polymyxin E, showed a lower synergy rate than polymyxin B in the time-kill assays, while an opposite result was found in the checkerboard microdilution method. Several reasons could result in the inconsistent result. First, polymyxin B and colistin are mixture of cyclic polypeptides, which contain up to 39 and 36 distinct lipopeptides, respectively, and differences in the structures of these individual polypeptides and variations in the physicochemical property among different polymyxin products or even batches from the same company can contribute to variability in the antibacterial activity of polymyxin B and colistin. 64 Second, the small sample size may skew the result though we performed a logit transformation for the event rate. Third, the time-kill method uses colony number as the judgment standard, while checkerboard microdilution and Etest methods use MIC in the formula. With no standardization of synergy test method, comparing results generated from different methods becomes a difficult Bedenic et al, 44 2016
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Vourli et al, 41 Table 2 , it seems that higher rates of synergy are seen with time-kill assays than with checkerboard or Etest assays, which is consistent with the conclusion drawn by Ni et al. 65 The synergy rate obtained from checkerboard microdilution and Etest methods is a static value and hard to reproduce. 66 In terms of time-kill assay, it is a useful method to provide us kinetic information of antibiotic interaction with bacteria although time-and labor-intensive for routine use in a clinical diagnostic laboratory. Therefore, developing new kinetic test method such as luciferase-based reporter system or standardizing the interpretation of these existing test methods for synergy evaluation should be a feasible strategy to address these limitations.
In time-kill assays, meropenem-polymyxin B combination showed the highest pooled synergy rate of 98.3%, which can be recognized as a very high degree of synergy to almost all isolates with different resistant profiles. Rifampicin in combination with meropenem displayed up to approximately 90% high synergy rate, and it is worth noting that amikacin may be a good partner of meropenem though only two studies can be found. Polymyxin B and amikacin are both molecules containing cations, which are capable of binding negatively charged lipopolysaccharides in the outer membrane of gram-negative bacteria, which thus leads to disruption of bacterial membrane permeability. 67 As to rifampicin, more studies should be conducted to confirm our preliminary finding, and the underlying mechanism of the combination also needs to be addressed. Polymyxins are considered as the last-resort antibiotic for the treatment of gram-negative bacteria; however, they were also reported to be associated with nephrotoxicity and neurotoxicity, 68 which often hindered their use in clinical settings. To reduce their toxicity, purification of polymyxins product and structure modification have been reported by several groups. 64 Sulbactam, as a member of serine β-lactamase inhibitor, is unable to inhibit any carbapenemases but displays moderate activity against A. baumannii, so a pooled synergy rate of 54.8% generated by meropenem-sulbactam combination was expected. Carbapenemases, especially metallo β-lactamases (MBLs), have caused extensive concern on their rapid dissemination and ability to hydrolyze almost all β-lactam antibiotics except monobactams. Unfortunately, up till now, no Laishram et al, 46 2016
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In vitro meropenem-based combination against A. Baumannii MBL inhibitor has been clinically approved and all clinically used β-lactamase inhibitors are not active toward MBLs. It remains a substantial challenge to design MBL inhibitors, especially for broad-spectrum MBL inhibitors.
Conclusion
The pooled synergy data in this review suggested that combination therapies of meropenem with polymyxin B, rifampicin, and possibly amikacin as well could achieve high synergy rates against MDR A. baumannii isolates, and colistin and sulbactam could be secondary choice for the combination with meropenem. Tigecycline and ciprofloxacin combination had the least pooled synergy rates. Compared to static checkerboard and Etest method, time-kill assay is more like in vivo dynamic antibacterial process and generally exhibited the greatest of synergisms because of its kinetic synergy calculation method. Combination therapies are future alternatives to traditional monotherapies for infections caused by MDR bacteria. However, the studies included in this review were performed in vitro, which neglects the complicated interactions between antibiotics and hosts. There is still a long way from our results to their applications in clinic, and findings of this review should be verified by more well-designed in vitro and in vivo studies. 
